IGeneX is a lab that’s been on the forefront of comprehensive testing for tick-borne illnesses for 25 years. IGeneX has developed several tests that are more sensitive and specific than others on the market. They were the first to identify Borrelia burgdorferi in ticks in California and Babesia microti in New York, Switzerland, and Australia with their patented Fluorescent In-Situ Hybridization (FISH) assay.   They were also first to produce a Tick-Borne Relapsing Fever (TBRF) Western Blot test. Relapsing Fever mimics many Lyme disease symptoms. IGeneX is the only lab that accurately provides the correct diagnosis by distinguishing Borrelia that causes Lyme disease from Borrelia that causes TBRF.   Other cutting-edge IGeneX tests include the Lyme ImmunoBlot IgM and IgG , which is one of the best tests available for Lyme disease with 98% specificity for IgM and 98.7% for IgG. The sensitivity of the Lyme ImmunoBlot is 90.9% with well-defined samples. It’s able to detect antibodies to major Borrelia burgdorferi sensu lato specific antigens from North America and Europe, specifically B. burgdorferi B31, B. burgdorferi 297, B. californiensis, B. mayonii, B. afzelii, B. garinii, B. spielmanii, and B. valaisiana.[1]   When the ImmunoBlot is paired with the IGeneX PCR assay, immunofluorescence (IFA) assay, and enzyme-linked immunospot (ELISPOT), the full spectrum of a patient’s immune response to infection as well as the disease stage is determined. We work with you to order the proper collection kits from IGeneX and determine which tests IGeneX will conduct with your sample. Unfortunately, IGenex doesn’t bill insurance except Medicare Part B, so you will probably have to pay out of pocket. [1]https://igenex.com/press-release/igenex-inc-introduces-new-diagnostic-tests-for-lyme-disease-and-tick-borne-relapsing-fever/